• Single IV cycle of PsiOxus’ T-SIGn vector enabled an otherwise non-effective dose of CAR-T cell therapy to clear primary and metastatic tumors in vivo • Reprogramming of the tumor… read more →
PsiOxus announced, today, an updated agreement to advance its clinical collaboration with Bristol Myers Squibb to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination… read more →
PsiOxus Therapeutics Ltd congratulates its very own Priya Mande, COO, as well as all the other award winners who have been recognised by The Healthcare Technology Report in their Top… read more →
PsiOxus, the gene therapy for cancer company, today announced that it has started a clinical trial with NG-641, a four transgene tumor-microenvironment modifying cancer gene therapy. This is the first… read more →
March 13, 2019 – OXFORD, UK – PsiOxus Therapeutics Ltd. (PsiOxus), the gene therapy for cancer company, today announced that it has started dosing NG-350A, an antibody based cancer gene… read more →
PsiOxus Therapeutics Ltd. (PsiOxus) and the Parker Institute for Cancer Immunotherapy (Parker Institute) announce a research project to investigate the use of PsiOxus’ virus-based gene therapy for treating solid tumors… read more →
December 12, 2017 –OXFORD, UK – PsiOxus Therapeutics, Ltd. (PsiOxus) today announced that the Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors, has… read more →
Treating solid tumors through the systemic delivery of oncolytic viruses. PsiOxus is very proud to also announce that we have been recognised by Fierce Biotech in this year’s Fierce 15.… read more →
The Sunday Times Hiscox Tech Track 100 league table ranks Britain’s 100 private tech (TMT) companies with the fastest-growing sales over their latest three years. It is compiled by Fast Track… read more →
(OXFORD, United Kingdom and PHILADELPHIA, United States. 16th August 2017) PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as… read more →
